Search

This article discusses the successful treatment of epidermal nevus (EN) in a patient with phacomatosis spilosebacea (PSS) using topical sirolimus. EN is a type of birthmark, while PSS is a rare disorder characterized by the presence of EN along with other organ system involvement. Treatment of EN can be challenging, but topical sirolimus has shown promising results in managing difficult-to-treat dermatological disorders. In this case, a patient with PSS experienced a marked decrease in thickness of the EN lesions after 5 weeks of treatment with topical sirolimus, with no adverse effects reported. Further follow-up is needed to confirm the long-term improvement. [Extracted from the article]

Juvenile xanthogranuloma (JXG) is a non-Langerhans cell histiocytosis usually occurring in infants and typically located in the head or neck.1 Clinically, solitary skin lesions are found in 60%-82% of patients and the most common variant is characterized by one yellowish nodule. Further studies are needed to help determine the efficacy and safety of this treatment in non-spontaneously resolved JXG and in other non-Langerhans cell histiocytoses limited to the skin, in which it could also be an alternative. In this respect, it is worthy of mention that characteristic histopathological clues of JXG as presence of xanthomatous/foamy histiocytes or Touton cells were not observed in any case.10 As noted above, spontaneous resolution of adult onset JXG is uncommon, and an area of atrophy frequently develops. [Extracted from the article]

Solid organ transplant recipients (SOTRs) exhibit an elevated incidence and aggressiveness of squamous cell carcinomas (SCCs) due to their immunosuppression. These tumors are associated with a heightened risk of metastasis and increased mortality. Therefore, an appropriate management of these patients is essential to improve their prognosis. Given the scarcity of studies on non-melanoma skin cancers (NMSCs) in SOTRs, this article aims to summarize and analyze the evidence gathered to date regarding therapeutic approaches, personalized monitoring, and prevention strategies for SCCs in these patients. Additionally, recent advancements in understanding SCCs within this patient group are also documented., (Copyright © 2024 Elsevier España, S.L.U. All rights reserved.)